VINC
Vincerx Pharma, Inc.
Industry
Biotechnology
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Loading...
Open
0.32
Mkt cap
10M
Volume
290K
High
0.33
P/E Ratio
-0.29
52-wk high
9.37
Low
0.32
Div yield
N/A
52-wk low
0.32
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.